HCSC is the largest customer-owned health insurer in the United States, operating Blue Cross and Blue Shield® Plans in Illinois, Montana, New Mexico, Oklahoma, and Texas Redwood City, CA, March 15, 2021 – Gynesonics®, a women’s healthcare company focused on the development of minimally invasive
Gynesonics Announces Centers for Medicare and Medicaid Services Final Rule Approves Ambulatory Surgery Centers as a Site of Service for Transcervical Uterine Fibroid Ablation with Device Intensive Designation
2021 Ruling Also Increases Hospital Outpatient Payment for the Associated Ambulatory Payment Classification That Covers the Sonata Treatment Redwood City, CA, March 9, 2021 – Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine
Gynesonics Announces that Detroit Medical Center Huron Valley-Sinai Hospital has Introduced Sonata, a New Innovative, Incision-Free Treatment for Symptomatic Uterine Fibroids
Detroit Medical Center’s Danny Benjamin, M.D., FACOG, Chief of Obstetrics and Gynecology at DMC Huron Valley-Sinai Hospital, is the first to provide the uterus-preserving, outpatient treatment option to women in Michigan Redwood City, CA, January 21, 2021 – Gynesonics®, a women’s healthcare
Sonata, a New Innovative, Incision-Free Treatment for Symptomatic Uterine Fibroids, has been Introduced in the MedStar Health System
MedStar Health is the first health system to provide Sonata, an incision-free, uterus-preserving, outpatient treatment option for women in the Maryland and Washington D.C. area Redwood City, CA - December 21, 2020 - Gynesonics®, a women’s healthcare company focused on the development of minimally
Sonata, A New Innovative, Incision-Free Procedure To Treat Symptomatic Uterine Fibroids, Expands in New York Area
Treatment provides women with a uterus-preserving, incision-free, outpatient option with significant symptom relief and fast recovery Redwood City, October 27, 2020 – Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine
Gynesonics Announces Publication of Long Term Three-Year Results of the SONATA FDA IDE Pivotal Trial
Outcomes Demonstrate Significant and Sustained Symptom Relief, High Patient Satisfaction, Improved Quality of Life and Low Reintervention Rates Redwood City, CA, October 13, 2020 – Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic
Gynesonics Introduces Sonata in Prominent New York City Fibroid Center
Sonata System Offers Innovative Incision-Free Fibroid Treatment Option For Women Suffering from Symptomatic Uterine Fibroids Redwood City, Calif., September 22, 2020 – Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine
Gynesonics Announces Brigham and Women’s Faulkner Hospital Becomes the First in Massachusetts to Offer Innovative New Procedure to Treat Symptomatic Uterine Fibroids
Sonata Treatment provides patients with an incision-free, outpatient option with exceptional results and fast recovery Redwood City, Calif. – September 3, 2020 – Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids,